PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Immunity. Author manuscript; available in PMC 2012 November 23.
Published in final edited form as:
PMCID: PMC3228524
NIHMSID: NIHMS338315

A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory

Summary

STAT3 transcription factor signaling in specific T helper cell differentiation have been well described, whereas the broader roles for STAT3 in lymphocyte memory are less clear. Patients with autosomal dominant hyper-IgE syndrome (AD-HIES) carry dominant negative STAT3 mutations and are susceptible to a variety of bacterial and fungal infections. We found that AD-HIES patients have a cell-intrinsic defect in the number of central memory CD4+ and CD8+ T cells compared to healthy controls. Naïve T cells from AD-HIES patients had lower expression of memory-related transcription factors BCL6 and SOCS3, a primary proliferation defect, and they failed to acquire central memory-like surface phenotypes in vitro. AD-HIES patients showed a decreased ability to control varicella zoster virus (VZV) and Epstein-Barr virus (EBV) latency, and T cell memory to both of these viruses was compromised. These data point to a specific role for STAT3 in human central memory T cell formation and in control of certain chronic viruses.

Introduction

T cell memory is critical to the maintenance of immunity against many common pathogens. An understanding of how T cell memory is generated and maintained is necessary to design rational therapies and vaccines to protect against infections. T cell receptor signal strength, costimulation, and the presence of cytokines all contribute to differentiation of naïve T cells into effector cells and memory cells (Cui and Kaech, 2010). In humans, it is thought that central memory T cells can home to the lymphoid organs and provide long-term T cell immunity through self-renewal, while effector memory T cells migrate to the periphery where they rapidly respond to secondary antigen exposure (Sallusto et al., 2010). The precise ontogeny of these populations along with the specific types of infections and pathogens against which they protect is not entirely understood.

Signal transducer and activator of transcription-3 (STAT3) is a latent cytoplasmic transcription factor with a wide variety of functions in mammalian cells (Levy and Lee, 2002). Within the immune system, STAT3 functions are noted in T cells, B cells, neutrophils, and macrophages amongst others. Particular attention has been paid to the effects of STAT3 on T and B cell maturation, differentiation, and function. The differentiation of several CD4+ helper T (Th) cell subsets including Th17 cells, follicular helper T cells, and possibly Th2 cells, appears to be dependent upon STAT3 (Eddahri et al., 2008; Nurieva et al., 2008; Vogelzang et al., 2008; Yang et al., 2007). Mice lacking Th17 cells or missing STAT3 within the CD4+ T cell compartment demonstrate impaired anti-fungal and anti-bacterial responses, poor germinal center formation, and defects in antibody production (Conti et al., 2009; Eddahri et al., 2008; Nurieva et al., 2008).

Several STAT3-dependent cytokines and transcription factors have critical roles in shaping CD8+ T cell memory responses in mouse models. IL-21 signaling, which depends on STAT3, promotes memory formation, sustained functionality, and, ultimately, viral clearance during chronic lymphocytic choriomeningitis virus (LCMV) infection (Elsaesser et al., 2009; Frohlich et al., 2009; Yi et al., 2009). IL-10 deficient mice infected with Listeria monocytogenes generate reduced numbers of memory T cells that fail to protect upon secondary challenge (Foulds et al., 2006). Other mouse models have revealed a critical role for STAT3-regulated transcription factors Blimp-1 (encoded by PRDM1) and Bcl6 (BCL6), both of which tend to counterregulate the other, in the generation of effector and central memory CD8 T cells respectively (Ichii et al., 2002; Ichii et al., 2004; Kallies et al., 2009; Rutishauser et al., 2009; Shin et al., 2009). Recent work has demonstrated an important role for SOCS3 in the control of chronic LCMV infections downstream of IL-6 signaling (Pellegrini et al., 2011). The direct mechanistic role the STAT3 pathway plays in human effector and central memory T cell generation and its role in CD4+ T cell memory in particular is not well understood.

Autosomal dominant Hyper-IgE Syndrome (AD-HIES) is caused by dominant negative STAT3 mutations and is characterized by recurrent mucocutaneous candidiasis, staphylococcal skin and lung infections, dermatitis, elevated IgE and a variety of skeletal and connective tissue abnormalities (Holland et al., 2007; Minegishi et al., 2007). Lymphocyte abnormalities previously observed in AD-HIES patients include defective Th17 cell differentiation (de Beaucoudrey et al., 2008; Ma et al., 2008; Milner et al., 2008; Renner et al., 2008), decreased CD45RA T cells in children compared to normal adults (Buckley, 1991; Young et al., 2007), decreased memory B cells (Speckmann et al., 2008), and an increased risk for Epstein-Barr virus (EBV) positive and EBV negative lymphoma formation (Kumanovics et al., 2010).

We used the opportunity presented by STAT3 mutant AD-HIES patients to examine the role of STAT3 in the generation and maintenance of lymphocyte memory. We found that these patients had increased numbers of naïve T cells and fewer central memory CD4+ and CD8+ T cells despite enhanced cell turnover in the absence of increased cell death. This observation appeared to be due to a defect in proliferation and differentiation from naïve precursors and diminished expression within the naïve compartment of transcription factors important for memory differentiation. As a potential consequence of the memory defects, HIES patients were found to have a previously unrecognized predisposition to develop varicella zoster virus (VZV) reactivation and EBV viremia.

Results

Patients with AD-HIES have fewer central memory T cells

We recruited a cohort of 19 AD-HIES patients and 10 age-matched healthy controls (ages 30–56) with mutations in the SH2, DNA binding, and transactivation domain of STAT3. We observed a decrease in the frequency of CD4+ and CD8+ central memory (CD3+ CD27+ CD45RO+) T cells in AD-HIES patients compared to controls (Figure 1A). The total numbers of CD4+ and CD8+ central memory (CD3+ CD27+ CD45RO+) T cells were significantly decreased in the AD-HIES patients (mean reduction of 45% in the CD4+ subset and 60% in the CD8+ subset) (Figure 1B). A corresponding increase was observed in the number of naïve (CD27+CD45RO) T cells in AD-HIES patients (Figure 1C). When compared to wild type naïve T cells, the CD27+CD45RO T cells from AD-HIES patients had similar expression of CD31, a marker of recent thymic emigrants (Figure S1A). Sorted CD31+CD27+CD45RO CD4 and CD8 T-cells from AD-HIES and control patients had similar numbers of T cell receptor excision circles (TRECs) and were consistent with previous reports in normal subjects (Kimmig et al., 2002) (Figure S1B). Additionally, CD28 expression and decreased expression of CD11a were similar in AD-HIES and control CD27+CD45RO CD4+ T cells (Figure SIC). Thus, AD-HIES CD27+CD45RO CD4+ T cells appear to be phenotypically and functionally naïve.

Figure 1
Patients with AD-HIES have fewer central memory T cells

Effector memory (CD3+ CD27 CD45RO+/−) T cell numbers were similar in both AD-HIES patients and controls (Figure S1D). CD127, an important central memory surface marker (Kaech et al., 2003), was lower in AD-HIES central memory T cells (Figure 1D and E, Figure S1E). Similar to recent clinical findings, we have not noted any correlation between the genotype of the AD-HIES patients and observed the central memory phenotype (Heimall et al., 2011). Patients with HIES therefore have a focal diminution in T cells with a central memory phenotype coupled with an apparent accumulation of naïve T cells.

AD-HIES T cells have an intrinsic defect in memory differentiation

We next examined if the observed defect in central memory T cell differentiation was intrinsic to the CD4+ and/or CD8+ T cells as opposed to a failure of help from other cellular sources or soluble mediators. A patient was identified with normal frequencies of central memory CD4+ and CD8+ T cells, yet they had two children with germline STAT3 mutations and abnormal central memory T cell counts (Figure 2A). The patient was found to be mosaic for an AD-HIES STAT3 mutation (Figure 2B and data not shown). Quantitative PCR measurement of the mutant STAT3 allele (G1145ASTAT3) from the AD-HIES mosaic patient found detectable mutant allele in the patient’s naïve CD4+ and CD8+ T cells but not in their central or effector memory T cells (Figure 2B and C). As a control, the frequency of an unlinked single nucleotide polymorphism (SNP) was determined to be 50% of alleles in naïve as well as memory T cell populations (Figure 2B). Of note, memory B cells from the mosaic patient had the same frequency of mutant STAT3 allele as naïve B cells, arguing against a B cell intrinsic defect, and suggesting that a different mechanism underlies the B cell memory deficit observed in AD-HIES (Figure 2D, Figure S2B) (Avery et al., 2010). The T cell intrinsic memory defect appears to be due in part to enhanced reliance upon IL-2 as in vitro expansion of sorted naïve CD4+ T cells from the STAT3 mosaic patient in the presence of IL-2Rα (Daclizumab) antibody resulted in a marked reduction of mutant STAT3 allele frequency after ten days in culture (Figure 2E). Thus the T cell memory defect in AD-HIES appears to be cell intrinsic, potentially due to increased reliance upon IL-2, while the B cell memory deficiency is not cell intrinsic.

Figure 2
AD-HIES T cells have an intrinsic defect in memory differentiation

Decrease in central memory T cells in AD-HIES is not due to differences in apoptosis or turnover

We investigated further the mechanisms for the reduction in central memory T cells in AD-HIES. The frequency of naïve and memory apoptotic T cells from 48-hour in vitro incubation was not significantly different between AD-HIES and control cells suggesting that death was not increased (Figure 3A). Cell turnover in vivo as measured by Ki67 expression in the T cell subsets was not diminished either (Figure 3B and C). Interestingly, turnover increased in the central memory and CD4+ T cell effector memory compartment of AD-HIES patients (Figure 3B and C). This increased cell turnover may be a homeostatic response to the relative reduction in central memory T cells, an interpretation supported in part by a detectable increase in serum IL-15 concentrations in AD-HIES patients (Figure 3D). No significant difference in IL-2 or IL-7 concentrations was observed in AD-HIES patients (Figure 3D). Therefore, the central memory defect in AD-HIES patients would not appear to be due to increased cell death or failure of central memory T cells to turnover sufficiently in vivo, but an increased reliance upon IL-2 for competitive fitness as well as a variable initial effector response may contribute to the phenotype.

Figure 3
Decrease in central memory T cells in AD-HIES is not due to increased ex vivo apoptosis or decreased in vivo division

Impaired in vitro induction of central memory T cell phenotypes

Given the observed increase in naïve T cells in AD-HIES patients and the decrease in CD127 expression within the central memory cells, we speculated that there might be a primary defect in the proliferation and differentiation of naïve T cells into cells with central memory phenotypes. Cultures of sorted naïve CD4+ and CD8+ T cells from most AD-HIES patients stimulated with anti-CD3 and anti-CD28 in the presence of IL-2 demonstrated impaired proliferation compared to healthy controls as measured by CFSE dilution and proportion of live blasting cells at the end of the culture (Figure 4A and Figure S3A–C) Sorted naïve T cells from two different samples obtained from a single AD-HIES patient cultured under the same conditions had similar blasting phenotypes when compared to their respective control implying that the ability to blast may not be highly variable within each patient (data not shown). This defect would not appear to be due to impaired activation and upregulation of CD25 (Figure S3D) despite evidence in mice that T cells deficient in STAT3 fail to efficiently upregulate CD25 upon activation (Akaishi et al., 1998). Additionally, we observed no link between the domain of STAT3 mutated in the patient and their ability to blast in vitro.

Figure 4
STAT3 mutant naïve T cells have impaired proliferation and in vitro induction of central memory T cell phenotypes

IL-7 and IL-15 have been demonstrated to play key roles in memory T cell homeostasis and differentiation (Kaech et al., 2003; Ku et al., 2000; Peschon et al., 1994). Short term in vitro stimulation and expansion of naïve T-cells in the presence of IL-2, IL-7 or IL-15 can lead to the differentiation into effector or central memory-like surface phenotypes in several mouse models, which correlate to their appropriate memory functions upon adoptive transfer (Carrio et al., 2004; Manjunath et al., 2001). Naïve T cells from AD-HIES patients were similarly stimulated for 4 to 6 days in the presence of IL-2, IL-7 (CD4+) or IL-15 (CD8+). In at least four individual experiments using four different patients and controls, we found that those AD-HIES T cells that did divide had a reduction, in some cases marked, in the frequency of CD45RO+CD62Lhi cells (Figure 4C and D, Figure S4A) in the presence of IL-7 (CD4) or IL-15 (CD8). In most cultures, upregulation of CD45RO was decreased in AD-HIES patients as a function of division number compared to controls (Figure S4B). Of note, IL-2 treatment alone did not appear to drive an effector memory phenotype as seen in the mouse models, perhaps reflecting differences between the species (Figure S4C and D). Regardless, using this human in vitro model, division of activated naïve T cells was markedly impaired, as was the capacity for dividing T cells with STAT3 mutations to differentiate into a central memory-like phenotype.

Naïve STAT3 mutant T cells have impaired expression of transcription factors related to central memory T cell differentiation

The impaired in vitro central memory differentiation was associated with decreased expression of two STAT3-responsive transcription factors important in the development of T cell memory, BCL6 and SOCS3 (Ichii et al., 2002; Ichii et al., 2004; Pellegrini et al., 2011), within the naïve T cell compartment of many AD-HIES patients (Figure 5A). The decreased presence of BCL6 and SOCS3 transcripts in AD-HIES naïve T cells, coupled with the proliferation defect may contribute to their decreased ability to become CD45RO+CD62Lhi in vitro as well as the increased naïve T cell pool and the lower numbers of central memory cells found in vivo.

Figure 5
STAT3 mutant naïve T cells have decreased central memory-related transcription factor expression

Central memory CD8 T cells had a more effector memory-like transcriptional profile in AD-HIES patients. In control subjects, BCL6 was elevated in the central memory CD8 T cells, and PRDM1 was elevated in effector memory populations in a pattern similar to that seen in mouse models of memory T cell differentiation (Figure 5B, Figure S5) (Rutishauser et al., 2009). However, sorted ex-vivo AD-HIES central memory T cells expressed less BCL6 than controls, and effector memory cells expressed more PRDM1 than controls (Figure 5B and C, Figure S5). The altered expression of these key transcription factors as well as the lower surface expression of CD127 also suggests that the fewer AD-HIES T cells which that succeed in differentiating in vivo into central memory T cells do not possess a typical central memory T cell phenotype which could therefore lead to defects in function independent of number. The failure to acquire central memory phenotypes may therefore be linked to impaired expression of STAT3-dependent transcription factors which are important for memory differentiation.

AD-HIES patients have an increased risk for VZV reactivation and EBV viremia

AD-HIES patients are highly susceptible to bacterial and fungal infections but appear to control primary viral infections normally (Freeman and Holland, 2010). In an attempt to find clinical correlates to the observed central memory T cell defects, we surveyed AD-HIES patients for evidence of impaired control of chronic viral infections. We found that nearly one third of AD-HIES patients had a history of reactivation of VZV (herpes zoster, shingles) at relatively young ages (Figure 6A and Table 1). Starting the second decade of life and onward, the incidence rates of reactivation were 20.6, 11.1, 17.6, and 70.2 cases, respectively, per 1000 person years (Table 1). These rates were 6- to 20-fold higher than the rate of herpes zoster in the general population (1 to 3 per 1000 person years) over the same decades of life (Donahue et al., 1995; Hope-Simpson, 1975; Yawn et al., 2007). The recurrence rate of herpes zoster in AD-HIES patients was 27.4 per 1000 person years after initial reactivation (5 of 19 patients, 26.3%) which is a substantial increase over the general population’s estimated rate of 7.4 per 1000 person years (Donahue et al., 1995).

Figure 6
AD-HIES patients have an increased risk for VZV reactivation and EBV viremia along with defects in virus-specific T cell memory
Table 1
Incidence of Herpes zoster in AD-HIES

While VZV-specific antibody titers in AD-HIES appear normal (Avery et al., 2010), we measured CD4+ T cell responses to VZV given that these cellular responses appear to be the most tightly correlated to risk for reactivation (Burke et al., 1982). We found that the increased incidence of herpes zoster in AD-HIES patients was associated with a reduction in the number of memory CD4+ T cells which produced either IL-2, IFNγ, or TNFα in response to VZV-infected cell lysate compared to controls, regardless of patient history of VZV reactivation (Figure 6B, Figure S6). The responding cell population was too small to differentiate central from effector memory phenotypes.

AD-HIES patients have an increased rate of lymphomas, a portion of which are EBV positive. We therefore measured EBV viremia and found that 54% of EBV antibody titer-positive AD-HIES patients had EBV+ peripheral blood mononuclear cells (PBMCs) while only 14% of controls had detectable EBV DNA in the blood. AD-HIES EBV+ PBMCs had markedly higher viral loads than EBV+ controls (Figure 6C). While the overall numbers of EBV-reactive memory CD4+ and CD8+ T cells were similar between AD-HIES patients and controls (Figure 6D), the EBV viremia observed in AD-HIES individuals was associated with lower frequencies of EBV-reactive central memory CD4+ and CD8+ T cells (Figure 6E and F). Cytomegalovirus (CMV) viremia, which can be better controlled when donor marrow is enriched for CMV-specific central memory T cells in transplant settings (Scheinberg et al., 2009), was not detected in the PMBCs of any AD-HIES patients or controls.

Discussion

AD-HIES patients have decreased numbers of central memory T cells due in part to an intrinsic defect in their ability to proliferate and differentiate from naïve precursors. Central memory CD8+ T cells from AD-HIES patients had a more effector-like transcriptional profile and both CD4+ and CD8+ central memory T cells had lower expression of CD127. The partial effacement of the central memory compartment in AD-HIES patients is associated with a failure to control VZV and EBV, but appears to largely confer sufficient protection against other viruses, including CMV, which is seen only in more severe settings of T cell compromise such as bone marrow transplant, severe combined immunodeficiency, and advanced HIV (Kost and Straus, 1996; Steininger, 2007). Other congenital immune deficiencies characterized by mature B cell (Faulkner et al., 1999; Winkelstein et al., 2006), or Th17 cell defects (Ferwerda et al., 2009; Glocker et al., 2009; Puel et al., 2011) are not associated with abnormal VZV or EBV responses, arguing against a role for those defects which are normally observed in AD-HIES as a cause for the diminished capacity to control chronic viruses. Additionally, the relatively intact naïve and effector memory pools may explain the failure to observe pathology from primary and recurrent viral infections in AD-HIES patients. This finding in AD-HIES appears unique in that no other known human immune deficiencies present from birth are characterized by increased rates of VZV reactivation in the absence of significant pathology when encountering primary VZV.

Our studies have revealed a role for STAT3 in CD4+ and CD8+ T cell memory separate from its role in T helper cell functional differentiation. STAT3 mutations in AD-HIES patients demonstrate a critical role for STAT3 and STAT3-dependent transcription factors in the development of central memory in CD8+ T cells and a previously unappreciated role for STAT3 in CD4+ T cell central memory development. Of note, LCMV infected GzmbCre/+ Stat3LoxP/LoxP mice or mice with Socs3 silenced in naïve CD8+ T cells have dramatically reduced frequencies of LCMV-specific central memory CD8+ T cells memory (Cui and Kaech, submitted). This work suggests that STAT3 signaling and SOCS3 expression within naïve T cells are key in steering CD8+ differentiation away from an effector phenotype and towards long-term central memory. The proliferation defect observed in AD-HIES naïve T cells could reflect a requirement for STAT3 pathway genes for normal naïve T cell division (Durant et al., 2010) or the failure of STAT3 genes to counter antiproliferative effects of other STAT pathways such as the IL-27-STAT1 pathway (Liu and Rohowsky-Kochan, 2011). The variability in the capacity for different patients’ naïve cells to proliferate may stem from the fact that STAT3 mutations in AD-HIES are hypomorphic, as opposed to null mutations. This diminished, but not absent function can lead to a wider clinical variability, as well as unstable cellular phenotypes such as the defects in neutrophil chemotaxis which can at times even vary within an individual patient (Donabedian and Gallin, 1983).

These newly observed clinical findings in AD-HIES may have other implications as well. Given that atopic dermatitis is a cardinal feature of AD-HIES, STAT3 pathway defects may also help explain an observed increased frequency of VZV reactivation in patients with severe atopic dermatitis (Rystedt et al., 1986; Veenstra et al., 1995). Additionally, the lower frequency of EBV-specific central memory T cells in AD-HIES may explain the observed increase in the number of EBV+ cells in the blood. While activation of STAT3 is associated with lymphomagenesis (Bromberg et al., 1999; Migone et al., 1995; Yu et al., 1995), the paradoxical increase in risk for B cell lymphomas in these patients with a loss of STAT3 function now may be understood as resulting from poor immune control of latently infected cells. This loss of immune control may explain the EBV+ lymphomas in AD-HIES and also may have effects on the overall control of tumorigenesis, which has been shown to be partially dependent on central memory T cells (Klebanoff et al., 2005). Patients with dysfunctional STAT3 signaling may need to be more closely monitored for control of VZV and EBV, and they may benefit clinically from early and perhaps frequently boosted VZV vaccination.

The specific defect in T cell central memory formation and associated loss of control of certain chronic viral infections we observed in AD-HIES illuminates our understanding of central memory T cell differentiation and the role of central memory T cells in immune responses. These insights may aid in the development of new monitoring and vaccination strategies for long-term control of chronic viral infections.

Materials and Methods

Subjects

AD-HIES patients and controls were enrolled under an Institutional Review Board-approved protocol 00-I-0159. The diagnosis of AD-HIES was based on both phenotypic analysis (a clinical score of >40 (Grimbacher et al., 1999)) and genetic sequencing of the STAT3 locus. Patients ranged in age from 2–58 years with a mean of 27 years. Males and females were equally represented. Thirty patients had mutations in the DNA binding domain, 27 had mutations in the SH2 domain, and 1 had a mutation in the transactivation domain of STAT3. Peripheral blood mononuclear cells were prepared from venous blood by Ficoll-gradient centrifugation and cryopreserved. Most patients were in a good health and admitted for annual well visits when samples were drawn.

Flow Cytometry

PBMCs were thawed, washed with PBS, and stained with aqua viability dye (Invitrogen, Carlsbad, CA) and the following surface and intracellular markers: CD3-Alexa700, CD8-PacificBlue, CD4-PECy5.5, -APC, CD27-FITC, -PECy5, CD4RO-TRPE, -PECy7, CD3-Alexa700, CD127-PE, CD62L-FITC, -V450, AnnexinV-FITC, -APC, 7AAD, Ki67-FITC, IL-2-APC, IFN γ-FITC, TNFα-PECy7 (all BD Biosciences, San Jose, CA). Events were collected on a LSRFortessa using Diva 6 software (BD Biosciences, San Jose, CA) and analyzed using FlowJo 9.1 and 9.3.1 software (Treestar, Ashland, OR). All plots gated on aqua negative (live) singlets excluding AnnexinV/7AAD staining. The CellTrace CFSE Cell Proliferation Kit (Invitrogen, Carlsbad, CA) was used according to the manufacturer’s protocol. Intracellular cytokine staining was performed using Cytofix/cytoperm (BD Biosciences, San Jose, CA). The FoxP3 staining kit and protocol (eBioscience, San Diego, CA) was used to stain for Ki67-FITC (BD Biosciences, San Jose, CA). Populations were sorted using gating strategies specified in the legends on an Aria II cytometer (BD Biosciences, San Jose, CA).

In vitro Stimulation

Expansion of mosaic T cells

Naïve T cells (aquaCD3+CD4+CD27+CD31+CD45RO and aquaCD3+CD8+CD27+CD31+CD45RO) were purified by flow cytometry and cultured in RPMI (Gibco, Carlsbad, CA) supplemented with 10% fetal calf serum (Gemini Bio-Products, West Sacramento, CA), 100 U/mL penicillin, 100 ug/mL streptomycin, and 29.2 ug/mL L-glutamine (all Gibco, Carlsbad, CA) (complete RPMI) in the presence of irradiated PBMCs and purified phytohaemagglutinin (3 μg/mL, Remel Inc, Lenexa, KS) for ten days. Anti-IL2Rα (i.e. Daclizumab, 2 or 20 μg/mL, Roche, Nutley, NJ) was added to cultures as indicated.

Memory T cell differentiation and naïve T cell stimulation

Naïve (aqua CD3+CD4+CD27+CD45RO and aquaCD3+CD8+CD27+CD45RO T cells were purified by flow cytometry and cultured in complete RPMI for four to six days. Some cells were labeled with CFSE prior to culture. Cells were stimulated with anti-CD3 (OKT3) (1 ug/mL, eBioscience, San Diego, CA) and anti-CD28 (0.5 ug/mL, BD Biosciences, San Jose, CA) with the addition of recombinant human IL-2 (20 U/mL, Peprotech, Rocky Hill, NJ), IL-7 (25 ng/mL, a gift from Crystal Mackall), and IL-15 (100 ng/mL, Peprotech,) as indicated.

Multiplex cytokine analysis

Plasma from patients and controls was tested for cytokine expression using the Meso Scale human assays for the indicated cytokines as per manufacturer’s instructions (Meso Scale Discovery, Gaithersburg, MD).

PCR Analysis

TCR Rearrangement Excision Circle (TREC) analysis

Quantification of TREC in sorted CD4+ and CD8+ T cells was done by real-time quantitative PCR with the 5′-nuclease (TaqMan) assay and an ABI7700 system (Perkin-Elmer, Norwalk, CT, USA) as previously reported (Douek et al., 2000). Cells were lysed in 100 mg/L proteinase K (Boehringer, Indianapolis, IN, USA) for 1 h at 56° C, then 10 min at 95° C, at 107 cells/mL. Real-time quantitative PCR was done on 5 μL of cell lysate with the primers: CACATCCCTTTCAACCATGCT and GCCAGCTGCA GGGTTTAGG, and probe FAM-5′-ACACCTCTGG TTTTTGTAAAGGTGCCCACT-3′-TAMRA (MegaBases, Chicago, IL, USA). PCR reactions contained 0.5 U Platinum taq polymerase (Gibco, Grand Island, NY, USA), 3.5 mmol/L MgCl2, 0.2 mmol/L dNTPs, 500 nmol/L each primer, 150 nmol/L probe, and Blue-636 reference (Megabases). Conditions were 95° for 5 min, then 95° for 30 s, 60° for 1 min, for 40 cycles. A standard curve was plotted, and the numbers of TREC in samples were calculated by the ABI7700 software.

STAT3 analysis

Cells sorted from the mosaic AD-HIES patient were washed in PBS and lysed in PureGene DNA Isolation Kit Cell Lysis Solution (Quaigen, Valencia, CA). Amplification of exons 12–14 of STAT3 was performed using 0.5 mM each primer, 12F amp- 5′-TAGTTTAAAGAAATGCCCAGGAGCACAGAGGTTTT-3′ and 14R amp- 5′-TTTGGCCTGAAGTGACTTTTTGGAATAACTACAGC-3′ with 10–100 ng of genomic DNA and Platinum Taq HiFidelity Supermix (Invitrogen, Carlsbad, CA). PCR products were analyzed on an agarose gel and purified with ExoSAP-IT (USB Corporation, Cleveland, OH). Sequencing was performed using Big Dye Terminators v3.1 (Applied Biosystems, Foster City, CA) and the following primers 13–14F 5′-CTGGGGACGTTGCAGCTCTCAGAGGGTAAGT-3′ and HpaII R 5′-CTCGGCCCCCATTCCCACATCTCT-3′. SNP genotyping primer probe sets for the known SNP in intron 13, rs2293152, and a custom pair designed to distinguish the 1145A mutation from the 1145G wildtype allele (Applied Biosystems, Foster City, CA) were used for quantitative PCR. Reactions were performed in triplicate using 20 ul volume with 10–100 ng DNA per reaction and 2X reaction mix (Applied Biosystems, Foster City, CA).

Transcript analysis

RNA was isolated using the RNeasy Mini Kit (Quiagen, Valencia, CA) as per manufacturer’s instructions. cDNA was reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA). Triplicate real-time PCR reactions were performed using 20 μL volume with 2X reaction mix and the following primers: 18S Hs99999901_s1, PRDM1 Hs00153357_m1, BCL6 Hs00277037_m1, and SOCS3 Hs01000485_g1 (Applied Biosystems, Carlsbad, CA). Transcripts were measured relative to 18S levels to normalize for cDNA input. STAT3 and transcript PCR reactions underwent 40 cycles and were analyzed on an ABI 7500 Real Time Thermal Cycler (Applied Biosystems, Carlsbad, CA).

Viral Memory Response

PBMCs were thawed and rested in complete RPMI for two hours. 1–2 × 106 cells were stimulated with Staphylococcus enterotoxin B as a positive control (Sigma, St. Louis, MO), EBV infected cell extract (Virusys Corporation, Taneytown, MD), or varicella zoster grade 2 antigen (Microbix Biosystems Inc., Ontario, CA) for two hours before the addition of Brefeldin A (10 μg/mL, Sigma, St. Louis, MO). After sixteen hours of stimulation, cells were washed twice with PBS and stained for flow cytometric analysis.

EBV Viral Titers

Cells were diluted in 1X RPMI Medium 1640 (Invitrogen, Carlsbad, CA) to obtain a final concentration of 1 × 106 cells/ml. DNA was extracted using the NucliSens easyMAG system (bioMerieux, Marcy I’Etoile, France) according to the manufacturer’s recommendations and eluted with 50 μl elution buffer. EBV quantitative real-time PCR (qPCR) was performed using the Rotor-Gene 3000 instrument (QIAGEN, Valencia, CA) with amplification and detection of a 192-bp segment from the BamHI-W gene using primers and dual hybridization probes described previously (Feng et al., 2004). The 20 μl reactions consisted of 1X QuantiTect Probe PCR master mix (QIAGEN) containing HotStarTaq DNA polymerase, reaction buffer, 4.0 mM MgCl2, dNTP mix (containing a dTTP/dUTP mixture), and ROX passive reference dye, and 0.5 μM of each primer, 0.2 μM of each probe, 0.5 U UNG, and 5 μl of extracted DNA. The reaction mixture was preincubated for 10 min at 30° C to activate UNG and then DNA was denatured and UNG inactivated at 95° C for 10 min. The EBV template was first amplified by five cycles of 15 s at 95° C and 40 s at 72° C followed by a touch-down procedure consisting of six cycles of 15 s at 95° C, 30 s at 72° C to 55° C with a 3° C decrease in annealing temperature at each cycle, and 30 s at 72° C. This was then followed by an additional 40 cycles of 15 s at 95° C, 30 s at 55° C, and 30 s at 72° C. Prior to extraction, each sample was spiked with an internal control (pBR322 plasmid DNA) to verify successful recovery of DNA and removal of PCR inhibitors. The internal control in extracted samples was detected by amplification in a separate qualitative real-time PCR as described previously (Cohen et al., 2010). A plasmid containing the EBV amplification sites in pCR2.1 vector (Invitrogen) were linearized and then diluted in TRIS-EDTA buffer (pH 8.0) with glycogen (33.3 μg/ml) to obtain a dilution series for the generation of a standard curve of 5 – 1 × 106 genome copies per reaction volume. For each positive sample, the Rotor-Gene 3000 software plotted the crossing threshold value on this curve to determine the number of target copies present in the amplification reaction.

Statistics

All error bars depict median values. Statistical significance was calculated from the median value using a one or two-tailed Mann-Whitney test using GraphPad Prism 5.0 software (GraphPad Software Inc., La Jolla, CA). Incidence rates for first occurrence of herpes zoster were determined by dividing the number of cases that occurred during the indicated decade of life by the number of person-years at risk lived during this decade. Exact confidence intervals for these rates were computed based on the assumption that the cases followed a Poisson distribution. Incidence rates for recurrence were calculated by dividing the number of cases of recurrence by the total person years after the first case of herpes zoster amongst those who already had herpes zoster until the current age or age at recurrence when present. The Kaplan-Meier plot of herpes zoster incidence and statistical significance was calculated using GraphPad Prism 5.0 software.

Highlights

  1. Patients with autosomal dominant hyper-IgE syndrome (AD-HIES) have fewer central memory CD4 and CD8 T cells than healthy controls.
  2. The defect in central memory differentiation in AD-HIES is T cell intrinsic. AD-HIES naïve T cells have impaired central memory differentiation in vitro, and the central memory T cells that do arise in AD-HIES patients have a more effector memory T cell transcriptional profile.
  3. AD-HIES patients have a decreased ability to control varicella zoster virus (VZV) and Epstein-Barr virus (EBV) latency, and T cell memory to both viruses is compromised.
  4. This work is the first description of a selective loss of the central memory compartment in humans.

Supplementary Material

01

Acknowledgments

The authors would like to thank all of the members of the Milner laboratory for their helpful discussions. We would like to thank the Flow Cytometry Core for all of their sorting assistance. We thank all of the patients and clinical staff whose dedication to human research was invaluable. This work was supported by the intramural research program of the NIAID.

Footnotes

Author Contributions

A.M.S., J.H., A.H., J.M.B., G.A.F., and J.D.M. performed experiments and analyzed data. J.H., A.F.F., S.M.H. and J.D.M. evaluated patients and obtained samples. E.B. performed statistical analysis. J.I.C. and D.C.D. provided sample material and analysis. A.M.S., J.H., and J.D.M. conceived the study, designed experiments, and interpreted data. A.M.S. and J.D.M. wrote the manuscript.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • Akaishi H, Takeda K, Kaisho T, Shineha R, Satomi S, Takeda J, Akira S. Defective IL-2-mediated IL-2 receptor alpha chain expression in Stat3-deficient T lymphocytes. Int Immunol. 1998;10:1747–1751. [PubMed]
  • Avery DT, Deenick EK, Ma CS, Suryani S, Simpson N, Chew GY, Chan TD, Palendira U, Bustamante J, Boisson-Dupuis S, et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med. 2010;207:155–171. [PMC free article] [PubMed]
  • Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE., Jr Stat3 as an oncogene. Cell. 1999;98:295–303. [PubMed]
  • Buckley RH, Schiff SE, Hayward AR. Reduced frequency of CD45RO+ T lymphocytes in blood of hyper-IgE syndrome patients. J Allergy Clin Immunol. 1991;87:313.
  • Burke BL, Steele RW, Beard OW, Wood JS, Cain TD, Marmer DJ. Immune responses to varicella-zoster in the aged. Arch Intern Med. 1982;142:291–293. [PubMed]
  • Carrio R, Bathe OF, Malek TR. Initial antigen encounter programs CD8+ T cells competent to develop into memory cells that are activated in an antigen-free, IL-7- and IL-15-rich environment. J Immunol. 2004;172:7315–7323. [PubMed]
  • Cohen JI, Fahle G, Kemp MA, Apakupakul K, Margolis TP. Human herpesvirus 6-A, 6-B, and 7 in vitreous fluid samples. J Med Virol. 2010;82:996–999. [PMC free article] [PubMed]
  • Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, Lindemann MJ, Ho AW, Hai JH, Yu JJ, Jung JW, et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med. 2009;206:299–311. [PMC free article] [PubMed]
  • Cui W, Kaech SM. Generation of effector CD8+ T cells and their conversion to memory T cells. Immunol Rev. 2010;236:151–166. [PubMed]
  • de Beaucoudrey L, Puel A, Filipe-Santos O, Cobat A, Ghandil P, Chrabieh M, Feinberg J, von Bernuth H, Samarina A, Janniere L, et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med. 2008;205:1543–1550. [PMC free article] [PubMed]
  • Donabedian H, Gallin JI. The hyperimmunoglobulin E recurrent-infection (Job’s) syndrome. A review of the NIH experience and the literature. Medicine (Baltimore) 1983;62:195–208. [PubMed]
  • Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med. 1995;155:1605–1609. [PubMed]
  • Douek DC, Vescio RA, Betts MR, Brenchley JM, Hill BJ, Zhang L, Berenson JR, Collins RH, Koup RA. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet. 2000;355:1875–1881. [PubMed]
  • Durant L, Watford WT, Ramos HL, Laurence A, Vahedi G, Wei L, Takahashi H, Sun HW, Kanno Y, Powrie F, O’Shea JJ. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity. 2010;32:605–615. [PMC free article] [PubMed]
  • Eddahri F, Denanglaire S, Bureau F, Spolski R, Leonard WJ, Leo O, Andris F. Interleukin-6/STAT3 signalling regulates the ability of naive T cells to acquire B cell help capacities. Blood 2008 [PubMed]
  • Elsaesser H, Sauer K, Brooks DG. IL-21 is required to control chronic viral infection. Science. 2009;324:1569–1572. [PMC free article] [PubMed]
  • Faulkner GC, Burrows SR, Khanna R, Moss DJ, Bird AG, Crawford DH. X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virus. J Virol. 1999;73:1555–1564. [PMC free article] [PubMed]
  • Feng WH, Cohen JI, Fischer S, Li L, Sneller M, Goldbach-Mansky R, Raab-Traub N, Delecluse HJ, Kenney SC. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst. 2004;96:1691–1702. [PubMed]
  • Ferwerda B, Ferwerda G, Plantinga TS, Willment JA, van Spriel AB, Venselaar H, Elbers CC, Johnson MD, Cambi A, Huysamen C, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med. 2009;361:1760–1767. [PMC free article] [PubMed]
  • Foulds KE, Rotte MJ, Seder RA. IL-10 is required for optimal CD8 T cell memory following Listeria monocytogenes infection. J Immunol. 2006;177:2565–2574. [PubMed]
  • Freeman AF, Holland SM. Clinical manifestations of hyper IgE syndromes. Dis Markers. 2010;29:123–130. [PMC free article] [PubMed]
  • Frohlich A, Kisielow J, Schmitz I, Freigang S, Shamshiev AT, Weber J, Marsland BJ, Oxenius A, Kopf M. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science. 2009;324:1576–1580. [PubMed]
  • Glocker EO, Hennigs A, Nabavi M, Schaffer AA, Woellner C, Salzer U, Pfeifer D, Veelken H, Warnatz K, Tahami F, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med. 2009;361:1727–1735. [PMC free article] [PubMed]
  • Grimbacher B, Schaffer AA, Holland SM, Davis J, Gallin JI, Malech HL, Atkinson TP, Belohradsky BH, Buckley RH, Cossu F, et al. Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet. 1999;65:735–744. [PubMed]
  • Heimall J, Davis J, Shaw PA, Hsu AP, Gu W, Welch P, Holland SM, Freeman AF. Paucity of genotype-phenotype correlations in STAT3 mutation positive Hyper IgE Syndrome (HIES) Clin Immunol. 2011;139:75–84. [PMC free article] [PubMed]
  • Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, Freeman AF, Demidowich A, Davis J, Turner ML, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med. 2007;357:1608–1619. [PubMed]
  • Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract. 1975;25:571–575. [PMC free article] [PubMed]
  • Ichii H, Sakamoto A, Hatano M, Okada S, Toyama H, Taki S, Arima M, Kuroda Y, Tokuhisa T. Role for Bcl-6 in the generation and maintenance of memory CD8+ T cells. Nat Immunol. 2002;3:558–563. [PubMed]
  • Ichii H, Sakamoto A, Kuroda Y, Tokuhisa T. Bcl6 acts as an amplifier for the generation and proliferative capacity of central memory CD8+ T cells. J Immunol. 2004;173:883–891. [PubMed]
  • Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol. 2003;4:1191–1198. [PubMed]
  • Kallies A, Xin A, Belz GT, Nutt SL. Blimp-1 transcription factor is required for the differentiation of effector CD8(+) T cells and memory responses. Immunity. 2009;31:283–295. [PubMed]
  • Kimmig S, Przybylski GK, Schmidt CA, Laurisch K, Mowes B, Radbruch A, Thiel A. Two subsets of naive T helper cells with distinct T cell receptor excision circle content in human adult peripheral blood. J Exp Med. 2002;195:789–794. [PMC free article] [PubMed]
  • Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005;102:9571–9576. [PubMed]
  • Kost RG, Straus SE. Postherpetic neuralgia--pathogenesis, treatment, and prevention. N Engl J Med. 1996;335:32–42. [PubMed]
  • Ku CC, Murakami M, Sakamoto A, Kappler J, Marrack P. Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science. 2000;288:675–678. [PubMed]
  • Kumanovics A, Perkins SL, Gilbert H, Cessna MH, Augustine NH, Hill HR. Diffuse large B cell lymphoma in hyper-IgE syndrome due to STAT3 mutation. J Clin Immunol. 2010;30:886–893. [PubMed]
  • Levy DE, Lee CK. What does Stat3 do? J Clin Invest. 2002;109:1143–1148. [PMC free article] [PubMed]
  • Liu H, Rohowsky-Kochan C. Interleukin-27-mediated suppression of human Th17 cells is associated with activation of STAT1 and suppressor of cytokine signaling protein 1. J Interferon Cytokine Res. 2011;31:459–469. [PMC free article] [PubMed]
  • Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong M, Grimbacher B, Fulcher DA, Tangye SG, Cook MC. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med. 2008;205:1551–1557. [PMC free article] [PubMed]
  • Manjunath N, Shankar P, Wan J, Weninger W, Crowley MA, Hieshima K, Springer TA, Fan X, Shen H, Lieberman J, von Andrian UH. Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J Clin Invest. 2001;108:871–878. [PMC free article] [PubMed]
  • Migone TS, Lin JX, Cereseto A, Mulloy JC, O’Shea JJ, Franchini G, Leonard WJ. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science. 1995;269:79–81. [PubMed]
  • Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, Kanno Y, Spalding C, Elloumi HZ, Paulson ML, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 2008;452:773–776. [PMC free article] [PubMed]
  • Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, Kawamura N, Ariga T, Pasic S, Stojkovic O, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007;448:1058–1062. [PubMed]
  • Nurieva RI, Chung Y, Hwang D, Yang XO, Kang HS, Ma L, Wang YH, Watowich SS, Jetten AM, Tian Q, Dong C. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity. 2008;29:138–149. [PMC free article] [PubMed]
  • Pellegrini M, Calzascia T, Toe JG, Preston SP, Lin AE, Elford AR, Shahinian A, Lang PA, Lang KS, Morre M, et al. IL-7 Engages Multiple Mechanisms to Overcome Chronic Viral Infection and Limit Organ Pathology. Cell 2011 [PubMed]
  • Peschon JJ, Morrissey PJ, Grabstein KH, Ramsdell FJ, Maraskovsky E, Gliniak BC, Park LS, Ziegler SF, Williams DE, Ware CB, et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med. 1994;180:1955–1960. [PMC free article] [PubMed]
  • Puel A, Cypowyj S, Bustamante J, Wright JF, Liu L, Lim HK, Migaud M, Israel L, Chrabieh M, Audry M, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332:65–68. [PMC free article] [PubMed]
  • Renner ED, Rylaarsdam S, Anover-Sombke S, Rack AL, Reichenbach J, Carey JC, Zhu Q, Jansson AF, Barboza J, Schimke LF, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol. 2008;122:181–187. [PubMed]
  • Rutishauser RL, Martins GA, Kalachikov S, Chandele A, Parish IA, Meffre E, Jacob J, Calame K, Kaech SM. Transcriptional repressor Blimp-1 promotes CD8(+) T cell terminal differentiation and represses the acquisition of central memory T cell properties. Immunity. 2009;31:296–308. [PMC free article] [PubMed]
  • Rystedt I, Strannegard IL, Strannegard O. Recurrent viral infections in patients with past or present atopic dermatitis. Br J Dermatol. 1986;114:575–582. [PubMed]
  • Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Immunity. 2010;33:451–463. [PMC free article] [PubMed]
  • Scheinberg P, Melenhorst JJ, Brenchley JM, Hill BJ, Hensel NF, Chattopadhyay PK, Roederer M, Picker LJ, Price DA, Barrett AJ, Douek DC. The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor. Blood. 2009;114:5071–5080. [PubMed]
  • Shin H, Blackburn SD, Intlekofer AM, Kao C, Angelosanto JM, Reiner SL, Wherry EJ. A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity. 2009;31:309–320. [PMC free article] [PubMed]
  • Speckmann C, Enders A, Woellner C, Thiel D, Rensing-Ehl A, Schlesier M, Rohr J, Jakob T, Oswald E, Kopp MV, et al. Reduced memory B cells in patients with hyper IgE syndrome. Clin Immunol. 2008;129:448–454. [PubMed]
  • Steininger C. Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system. Clin Microbiol Infect. 2007;13:953–963. [PubMed]
  • Veenstra J, Krol A, van Praag RM, Frissen PH, Schellekens PT, Lange JM, Coutinho RA, van der Meer JT. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS. 1995;9:1153–1158. [PubMed]
  • Vogelzang A, McGuire HM, Yu D, Sprent J, Mackay CR, King C. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity. 2008;29:127–137. [PubMed]
  • Winkelstein JA, Marino MC, Lederman HM, Jones SM, Sullivan K, Burks AW, Conley ME, Cunningham-Rundles C, Ochs HD. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore) 2006;85:193–202. [PubMed]
  • Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, Dong C. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem. 2007;282:9358–9363. [PubMed]
  • Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341–1349. [PubMed]
  • Yi JS, Du M, Zajac AJ. A vital role for interleukin-21 in the control of a chronic viral infection. Science. 2009;324:1572–1576. [PMC free article] [PubMed]
  • Young TY, Jerome D, Gupta S. Hyperimmunoglobulinemia E syndrome associated with coronary artery aneurysms: deficiency of central memory CD4+ T cells and expansion of effector memory CD4+ T cells. Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology. 2007;98:389–392. [PubMed]
  • Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, Jove R. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science. 1995;269:81–83. [PubMed]